BiBo will construct a production facility specifically designed to supply the Company with pegozafermin for commercialization, if approved. Under the Collaboration Agreement, the Company will pay BiBo an aggregate of $135 million toward the construction of the Production Facility, of which 45% of the Payment will be payable in the third quarter of 2024. The remainder of the Payment will become payable upon achievement of certain specified milestones, of which up to an additional approximately 45% of the Payment could become payable within the next 12 months, depending on the timing of achievement of certain milestones.